Background and Aims: This study was aim to investigate the relationship between the four intron SNPs (rs3087404, rs2029167, rs2029166 and rs7296239) of SMUG1 and the susceptibility of cervical squamous cell carcinoma.
Introduction
Around the world, cervical cancer (CC) is the fourth most common cancer among women, accounting for an estimated 529,572 diagnosed new cases and 274,967 deaths per year [1]. This cancer is the 3rd-leading cause of death in women' neoplasis worldwide and the morbidity of cervical cancer has increased recently [2]. In China, the cervical cancer has become the first major female cancer (98.9 per 100000) in addition to breast cancer. The mortality rate is up to 30.5 per 100000. And the incidence rate has the increasing trends [3].
Although several factors that contribute to cervical cancer development have been identifiedmainly intrinsic factors (genetic), and extrinsic factors belonging to the high risk Human Papillomavirus (HR-HPV)-genetic factors show great potential as susceptibility or prognosis indicators [4,5]. Only a small fraction (~1%) of cervical HR-HPV infection outcomes to cervical neoplasia, and the factors determining risk of progression are not entirely understood [6]. Many genetic variants were associated with the risk of cervical cancer as supported by the epidemiological evidence [7] .
Genomic instability due to DNA damage by carcinogens has been implicated in the initiation and development of cancer. DNA damage response and repair counteract the threats to genomic integrity, and variations in DNA repair capacity resulting from genetic variants could correlate with cancer predisposition [8-11]. The base excision repair (BER) pathway is the major DNA genetic damage repair pathway involved in genomic instability and tumorigenesis. Previous candidate gene studies showed that selected functional single nucleotide polymorphisms (SNP) in BER genes are associated with higher risk of several solid cancers [12-17].
Single-strand selective mono-functional uracil-DNA glycosylase (SMUG1) is one of the BER genes which remove uracil from double-stranded and single-stranded DNA to maintain genomic stability following oxidative attacks [18]. SNPs in this gene could have an effect on its enzyme capability of repairing DNA damage.
Xie et al evaluated the associations of 167 SNPs from 19 genes of the BER pathway with the risk of bladder cancer. 13 SNPs in 10 BER pathway genes were significantly associated with bladder cancer risk. The most significant SNP was rs2029167 in the SMUG1 gene [19] . Similar studies also found a correlation between SNP of SMUG1 with breast cancer [20] and colorectal cancer (CRC) [21] . Until now, there is no report of SNP of SMUG1 in cervical cancer.
In this large scale case-control study, the aim was to investigate the relationship between the four intron SNPs (rs3087404, rs2029167, rs2029166 and rs7296239) of SMUG1 and the susceptibility of cervical squamous cell carcinoma (CSCC). Genotyping analyses of the four SMUG1 SNPs were performed in 400 CSCCs, 400 precursor lesion CIN III and 1200 normal controls.
Materials and methods

Study samples selection
400 CSCC cases, 400 CIN III cases and 1200 normal controls were recruited from Zhejiang Province, China. The diagnosis was determined by two pathologists. All subjects were unrelated ethnic Chinese women and recruited between 2004 Jun to 2008 Dec. Normal controls were randomly selected from healthy women volunteers during gynecologic examinations. The inclusion criteria for healthy volunteers were without gynecological neoplasm, cytological findings, endometriosis, other solid cancer and immune disorders.
Patients with pathological diagnosis of CINIII and cervical squamous cell carcinoma (CSCC) were included in the study. Considering that patients with CINI and CINII have unstable disease progression, we excluded these patients and only selected patients with CINIII. All cases of CSCC were FIGO stage Ia-IIb, histologically confirmed primary cervical carcinoma, treated radical hysterectomy with pelvic lymph node dissection, and did not receive any anticancer therapy prior to their surgery. Patients who are eligible for any of the following criteria are excluded: over 70 years of age, with other serious complications, or previous malignant disease.
Of these, 201 CSCC patients, 357 CIN III patients and 609 normal controls agreed to provide cervical brush-off samples for detecting HR-HPV. This study was approved by the Medical Ethical Committee of Women's Hospital, School of Medicine, Zhejiang University (No.2004002) . All patients signed informed consent.
DNA Extraction and Genotyping
Genomic DNA was extracted from anticoagulant peripheral blood using a DNA extraction kit according to the manufactor's guideline (Sangon Bioengineering Co., Shanghai, China). All DNA samples were dissolved in water and hypothermic preservation ready to use.
The 
The PCR was performed in a 25ul reaction mixture, containing 50 ng of genomic DNA, 5.0 pmol of each primer, 0.2 mM of each dNTP and 1.0U of Taq DNA polymerase (TAKARA, Dalian, China). PCR undertook the following conditions: an initial denaturation at 94°C for 5 min, followed by 35 cycles of 94°C for 30s, 57°C for 30s, and 72°C for 1min, and a final step of 72°C for 10min. The PCR products were developed by 1.5% agarose gel electrophoresis, stained with ethidium bromide and visualized with a TyphoonTM 9410 Imaging System (GE Healthcare, USA). All samples were tested twice in double blind by two different technicians, and the reproducibility of the experiment was 100%.
HR-HPV detection
HR-HPV infection was identified using the Hybrid Capture II(HC II) assay (Digene Diagnostics Inc., Gaitherburg, MD, USA) using probe B, which includes a pool of RNA probes for 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 68. Cervical sampling for HR-HPV DNA was performed with the Digene Cervical Sampler.
SMUG1 mRNA expression by qRT-PCR
Freshly frozen tumor tissues of eighty seven CSCCs were selected. Total RNA was extracted using Trizol reagent according to the manufacturer's protocol (Invitrogen, USA). Total RNA was treated with RNase-free DNase I. cDNA was reversed transcription and used as a template for qPCR detection. The following PCR primer pairs were used for quantitative amplification; 95°C 30s, 40 cycles at 95°C 5s followed with 60°C 30s. The primers of SMUG1 (mRNA: NM_001243787.1) were 5'-CGCAACTACGT GACTCGCTA-3'; 5'-GTCCCAGCACTGGTCGTTTA-3'. GAPDH was used as internal control. The primers of GAPDH (mRNA: NM_001256799.2) were 5'-GAGA AGGCTGGGGCTCATTT-3'; 5'-AGTGATGGCATGG ACTGTGG-3'. The PCR product length of SMUG1 and GAPDH were 190bp and 231 bp, respectively. All reactions were performed with a ViiA 7 Dx System (ABI). The cutoff point (Ct) was defined as the value when the fluorescent signal increased above the background threshold. The ΔCt for gene-specific mRNA expression was calculated relative to the Ct of GAPDH. Relative mRNA expression was calculated with the formula: 2 -ΔCt .
SMUG1 protein expression by Western blotting
Eighty seven freshly CSCCs tissues were used to detect SMUG1 protein expression. Briefly, the tissue samples were minced on ice, and then the tissue was homogenized in the RIPA protein lysis buffer. The homogenized mixtures were rotated in the tubes at 4℃ for 1 h, and after centrifugation at 12,000 rpm at 4℃, the supernatant was collected and the protein concentrations were quantified.
10μl protein lysates were loaded into an 8% PAGE gel. Subsequently, electrophoretic separated proteins were transferred onto a 0.45µm PVDF membrane. After blocking with 5% non-fat milk for 1h, PVDF membrane was incubated with primary mouse monoclonal antibodies: SMUG1 (1:2000) purchased from NOVUS Biologicals (Cat No. H00023583-M07) and GAPDH (1:5000) purchased from Proteintech(Cat No. Cat.60004-1-Ig) for 4°C overnight, then were washed with TBS containing 0.05%Tween-20 for three times, followed by a 1h incubation with an HRP-conjugated secondary antibody (1:5000). After washing with TBS, the membranes were imaged with ECL using an Image Quant LAS 4000 mini (GE Healthcare).
Statistical Analysis
For the association between the genotypes and risk of cervical carcinoma, the odds ratio (OR), 95% confidence intervals (CIs) and P-values were obtained by binary logistic regression analysis. The control was set as the reference group for analysis. Stratified analysis of life style habits and genotype frequencies were evaluated with Kruskal-Wallis H test. The differences of quantitative mRNA and protein expression were calculated by ANOVA with a post hoc analysis (Fisher least significant difference). All reported values are two-tailed. The level of statistically significant difference was set at P≤0.05. All statistical analysis was done with SPSS software 18.0 ver for Windows.
Results
Clinical Features of Cases and Controls
40 years old/40 years old individuals were 602/598, 258/ 142 and 160/240 in the control, CIN III and carcinoma respectively. The carcinoma group had significantly more individuals >40 years old, but the CIN III group had more <40 years old individuals (P<0.001) compared to the control. There was no significant difference beside the increase of the proportion of individuals with number of parities more than 3 in the CIN III and carcinoma groups. The HR-HPV infection rate was 31.4%, 86.8% and 88.6% in the control, the CIN III and the carcinoma, respectively. HR-HPV infection in CIN III and cervical carcinoma cases were more than in controls. The Table 2 and data are quoted from our previously published work [23]. .000]. We observed "A" allele is the major form at rs3087404 in controls (62.0%, 1487/ 2400), but "G" allele is the major form in CSCCs (53.4%, 427/800). The increased risk of "G" allele in CIN III and CSCCs were 1.78(1.00-1.39) and 1.86 (1.59-2.19) respectively. Data also indicated that individuals with "G" allele or "G" carrier (AG +GG) at rs3087404 were at higher risk for CSCCs [OR=1.34 (1.04-1.71), P= 0.022].
Correlation analysis of SMUG1 SNPs Genotypes with risk of CSCC
The AA, AG, and GG frequency of SMUG1 rs2029167 was 37.9%, 44.3% and 17.8% in the controls, 30.3%, 33.5% and 36.3% in the CIN III, 24.3%, 29.8% and 46.0% in CSCCs, respectively. These results revealed that women with the homozygous GG of rs2029167 had an increased risk of CIN III [OR=2.56 (1.91-3.43), P= 0.000] and CSCCs [OR=4.05(3.02-5.44), P=0.000]. "A" allele is the major form at rs2029167 in controls (60.1%, 1442/2400), but "G" allele is the major form in CIN III (53.0%, 424/800) and in CSCCs (60.9%, 487/800). "G" allele at rs2029167 was significantly higher in CIN III and CSCCs compared with normal controls. The increased risk of "G" allele in CIN III and CSCCs were OR=1.70(1.45-1.99) and OR=2.34(1.99-2.76) respectively. "G" allele or "G" carrier (AG +GG) at rs2029167 were at higher risk for CINIII [OR=1.41(1.10-1.80), P= 0.006] and CSCCs [OR=1.91 (1.48-2.47), P= 0.000].
As show in Bold values show statistical data with significant difference. *All P-values are adjusted for age, number of sexual partners, age at first intercourse, parities (including full-term pregnancy and abortion at or after 28 weeks) and age at first full-term pregnancy. Bold values show statistical data with significant difference. *All P-values are adjusted for age, number of sexual partners, age at first intercourse, parities (including full-term pregnancy and abortion at or after 28 weeks) and age at first full-term pregnancy.
Association between SMUG1 rs3087404, rs2029167 polymorphisms and the Sexual, Reproductive History in CSCCs and CIN III As show in Table 5 , the participants were divided into two groups according to Age, age of first sexual intercourse, number of sexual partners, age at first parity, number of parities and HR-HPV infection, then stratified analysis was done with the SMUG1 rs3087404 (A/G) and rs2029167 (A/G) genotype. Stratified analysis of age, number of parities, and age at first parity showed no correlation with rs3087404 (A/G) polymorphisms. However, we find a particularly high level of enrichment between groups with stratified analysis of the number of sexual partners in the CIN III (χ 2 =15.610, P=0.000) and CSCCs (χ 2 =13.468, P=0.000), and the age of first sexual intercourse in the CIN III (χ 2 =18.453, P=0.000) and CSCCs (χ 2 =15.528, P=0.000). We also did not find a high level of enrichment between HR-HPV positive and negative group of CIN III (χ 2 =0.176, P=0.675) and CSCCs (χ 2 =0.017, P=0.895).
Data display of rs2029167 (A/G) as show in Table 6 , we did not find a particularly high level of enrichment between groups, except for the number of sexual partners in the CIN III (χ 2 =10.214, P=0.001) and CSCCs (χ 2 =12.366, P=0.000), there was a particularly high level of enrichment.
Association between SMUG1 rs3087404, rs2029167 polymorphisms and the Clinical pathological characteristics in CSCCs
The correlation of SMUG1 rs3087404 and rs2029167 polymorphisms with CSCCs clinicopathological characteristics is shown in Table 7 .The CSCCs were divided into two groups according to age, tumor family history, FIGO stage, tumor size, differentiation grade, lymph node metastasis, vascular involvement, stromal invasion, vaginal wall extension, parametrial extension, and endometrial extension, then stratified analysis was done with the SMUG1 rs3087404 (A/G) and rs2029167 (A/G) genotype.
Stratified analysis of age, FIGO stage, tumor size, lymph node metastasis, vascular involvement, stromal invasion, vaginal wall extension, parametrail extension, and endometrial extension showed no correlation with rs3087404 (A/G) or rs2029167 (A/G) polymorphism. However, we found a particularly high level of enrichment of rs3087404 (χ 2 =9.265, P= 0.002)) and rs2029167 (χ 2 =8.112, P=0.004) when stratified by differentiation grade. This means that GG homozygotes of rs3087404 and rs2029167 are significantly associated with the degree of malignancy of tumor differentiation. In addition, interestingly, we found that GG homozygote of rs3087404 is also associated with a family history of the tumor (χ 2 =8.792, P=0.003).
mRNA and protein expression from patients with different genotypes of SMUG1 rs3087404 (A/G) or rs2029167 (A/G)
As shown in Figure 1 , among the 87 CSCCs patients, the genotypes of AA, AG, and GG at rs3087404 were 25(28.7%), 32(36.8%) and 30(34.5%) cases, while the genotypes of AA, AG, and GG at rs2029167 were 22(25.3%), 26(30.0%) and 39(44.8%) cases, respectively. There was no significant difference in the expression of SMUG1 mRNA with different genotypes at rs3087404 (F=1.022, P=0.364) or at rs2029167 (F=2.067, P=0.133).
As shown in Figure 2 , Western Blot experiments confirmed that the polymorphism of rs3087404 did not affect the expression of SMUG1 protein (F=0.254, P=0.781). Similarly, the polymorphisms of rs2029167 is also independent of the expression level of SMUG1 protein (F=1.346, P=0.308). 
Haplotype Analysis between the Linkage Disequilibrium of the SMUG1 rs3087404 and rs2029167 Variants Genotypes and the Risk of CIN III and CSCCs
Since that the frequencies of both rs3087404 (A/G) and rs2029167 (A/G) genotypes change the risk of CIN III or CSCCs significantly, we further analyzed the linkage disequilibrium between rs3087404 (A/G) and rs2029167 (A/G). The frequencies of the nine haplotypes were shown in Additionally, most GG (rs3087404) genotypes were linkage GG-AG (44/77, 80/140) in the CIN III and CSCC, while most GG (rs2029167) genotypes were linkage genotype AG-GG (79/145, 112/184) in the CIN III and CSCCs, respectively. These indicated that the majority of GG genotype distributions are caused by the linkage disequilibrium with the corresponding alleles. Bold values show statistical data with significant difference. Stratified analysis were applied by the Kruskal-Wallis H. A P value less than 0.05 was considered significant. . These reports remind us to make a hypothesis which there is an association between the genetic variants of SMUG1 gene with cancer risk. We carried out the correlation study of cervical cancer and SMUG1 SNPs.
The initiation and development of cervical carcinoma involves reversible transformation in the cervical squamous cells resulting in various cellular abnormalities and ultimately to cervical tumorigenesis. The development of cervical carcinoma usually requires multiple stages, eventually developing from precursor lesion cervical intraepithelial neoplasia (CIN) to cervical malignant carcinoma [21]. In our results, the two of SMUG1 rs2029166 and rs7296239 polymorphisms were not associated with the risk for CIN III or CSCC. Interestingly, the homozygous GG of rs3087404 and rs2029167 had a significantly increased risk of CIN III and CSCC. We also observed the increased risk of G allele of these two SNP in CIN III and CSCC. The individuals with G allele or G carrier (AG +GG) at rs3087404 and rs2029167 were at higher risk for CSCC. These findings indicated that the SMUG1 rs2029166 and rs7296239 polymorphisms (G allele) maybe play a role in initiation and progression of precancerous lesions (CIN) and cervical carcinoma. So far, there is no study about the correlation between cervical carcinoma and the SMUG1 rs2029166 and rs7296239 polymorphisms (G allele). The present study is the first time to discover the association between the SMUG1 rs2029166 and rs7296239 polymorphisms (G allele) and cervical carcinoma or CIN III. In general, SNP loci that affect the structure and function of genes are located in the 5' UTR promoter, coding region, or 3' UTR region. Although our two variants both are located in the intron which cannot change the amino acid, it is possible that there is linkage disequilibrium with other functional genetic variants and serves as a genetic marker of susceptibility [41]. Another possibility is that the SMUG1 rs2029166 and rs7296239 genetic variants maybe influence primary mRNA splicing and regulation, and affects SMUG1 protein expression or produce alternative spliceosome. To validate the SMUG1 expression change, we detected the mRNA and protein expression in fresh tumor tissues in the different genotype groups of SMUG1 rs2029166 and rs7296239, but we discovered that there was no association between the genotype of SMUG1 rs2029166 and rs7296239 with SMUG1 gene mRNA or protein expression. These indicate that the tumor susceptibility induced by the polymorphism of this locus was not achieved by altering gene expression. Bonnet et al. speculated that the introns take participate in maintaining genetic stability at certain locations, particularly in highly expressed genes [42], and repair genes are often high expression genes.
During the linkage disequilibrium analysis between rs3087404 (A/G) and rs2029167 (A/G), we found that whether the rs3087404 or rs2029167 is GG homozygote, the linkage mode is at high risk. Additionally, most GG (rs3087404) genotypes were linkage GG-AG (44/77, 80/140) in the CIN III and CSCCs, while most GG (rs2029167) genotypes were linkage genotype AG-GG (79/145, 112/184) in the CIN III and CSCCs, respectively. These indicated that the majority of GG genotype distributions are caused by the linkage disequilibrium with the corresponding alleles. These linkage modes can be used as genetic biomarker of early prediction of cervical carcinoma, as an indicator of primary prevention.
Stratified analysis of the number of sexual partners and the age of first sexual intercourse found that the rs3087404 (A/G) had a particularly high level of enrichment in the CIN III and CSCCs. About the rs2029167 (A/G), we only found a particularly high level of enrichment grouping by the number of sexual partners in the CIN III. This suggests that there may be a certain correlation between SMUG1 rs3087404 (A/G) and rs2029167 (A/G) variants with the female sexual behavior.
Among all of clinical parameters, we found that the genetic polymorphisms of rs3087404 (A/G) and rs2029167 (A/G) are significantly associated with the degree of malignancy of tumor differentiation; homozygous GG genotype increases the risk of malignant cell differentiation grade of tumors. In addition, interestingly, we found that GG homozygote of rs3087404 is also associated with a family history of the tumor. These indicate that there maybe a correlation between the SNPs of SMUG1 rs3087404 (A/G) and rs2029167 (A/G) with tumor cell differentiation and family heredity.
In HR-HPV positive group, we found that the homozygous GG of rs3087404 and rs2029167 both significantly increased the risk of CSCCs, only "G" allele or "G" carrier (AG +GG) at rs2029167 were at higher risk for CSCCs. But, in stratified analysis, we did not find a high level of enrichment between HR-HPV positive and negative groups of CIN III and CSCCs. These indicated that the rs3087404 and rs2029167 involved in the cervical tumorigenesis, but they maybe not affect the HR-HPVs infection at early onset of disease. In the process of affecting cervical tumorigenesis, rs2029167 variant may be more effective than those of rs3087404 variant.
These findings suggested that there was association between the two of SMUG1 rs3087404 (A/G) and rs2029167(A/G) genetic variant with the susceptibility of CIN III and CSCCs, but not HR-HPVs infection. Whether the rs3087404 or rs2029167 is GG homozygote, there was linkage disequilibrium between these two of polymorphism leading to increase the risk of CIN III and CSCC. These linkage modes can be used as genetic biomarker of early prediction of cervical carcinoma, as an indicator of primary prevention.
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